Principal Investigator

Jing Jing Wang, MD

Site-PI

Michael Benatar, MD, PhD

Summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immune suppressive agents. Eculizumab is a monoclonal antibody that inhibits the complement pathway. It has previously been shown to be effective in treating patients with paroxysmal nocturnal hemoglobinuria.

Eligibility criteria

• Generalized myasthenia gravis, onset within last 10 years
• Positive acetylcholine receptor binding antibodies
• Age 18-80
• MGFA class II-IVa
• QMG Score ≥ 12 (with minimum score of 2 in at least 4 items)
• Failed at least two immune suppressive agents after one year of treatment
• No thymoma
• No current or chronic use of plasma exchange
• No IVIg within 8 weeks prior to screening

Funding agency

Alexion Pharmaceuticals

Collaborators

Links

http://clinicaltrials.gov/ct2/show/NCT00727194?term=benatar&rank=6

Presentations / Publications